全文获取类型
收费全文 | 225744篇 |
免费 | 4477篇 |
国内免费 | 181篇 |
专业分类
耳鼻咽喉 | 1713篇 |
儿科学 | 7656篇 |
妇产科学 | 3765篇 |
基础医学 | 23003篇 |
口腔科学 | 2219篇 |
临床医学 | 16978篇 |
内科学 | 43067篇 |
皮肤病学 | 1179篇 |
神经病学 | 21336篇 |
特种医学 | 10888篇 |
外科学 | 36882篇 |
综合类 | 2885篇 |
一般理论 | 65篇 |
预防医学 | 21503篇 |
眼科学 | 3630篇 |
药学 | 12467篇 |
中国医学 | 672篇 |
肿瘤学 | 20494篇 |
出版年
2023年 | 286篇 |
2022年 | 602篇 |
2021年 | 1436篇 |
2020年 | 903篇 |
2019年 | 1304篇 |
2018年 | 23297篇 |
2017年 | 18283篇 |
2016年 | 20489篇 |
2015年 | 2309篇 |
2014年 | 2919篇 |
2013年 | 3222篇 |
2012年 | 11148篇 |
2011年 | 25013篇 |
2010年 | 20994篇 |
2009年 | 13521篇 |
2008年 | 22995篇 |
2007年 | 25248篇 |
2006年 | 4188篇 |
2005年 | 5740篇 |
2004年 | 6560篇 |
2003年 | 7252篇 |
2002年 | 5140篇 |
2001年 | 566篇 |
2000年 | 623篇 |
1999年 | 479篇 |
1998年 | 677篇 |
1997年 | 635篇 |
1996年 | 438篇 |
1995年 | 419篇 |
1994年 | 343篇 |
1993年 | 292篇 |
1992年 | 180篇 |
1991年 | 209篇 |
1990年 | 233篇 |
1989年 | 178篇 |
1988年 | 142篇 |
1987年 | 109篇 |
1986年 | 107篇 |
1985年 | 138篇 |
1984年 | 144篇 |
1983年 | 129篇 |
1982年 | 161篇 |
1981年 | 109篇 |
1980年 | 134篇 |
1978年 | 69篇 |
1977年 | 62篇 |
1976年 | 57篇 |
1974年 | 61篇 |
1938年 | 61篇 |
1932年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
131.
Robert C. Flanigan Joseph H. Saiers Michael Wolf Eric H. Kraut Anthony Y. Smith Brent Blumenstein E. David Crawford 《Investigational new drugs》1994,12(2):147-149
Summary The Southwest Oncology Group (SWOG) studied the response rate and toxicity of merbarone (1,000 mg/m2 IV continuous infusion days 1–5, q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 36 eligible patients, there was one partial response for a response rate of 3% (95% C.I. 0.1–15%). There were no mixed responses. There were no treatment related deaths or adverse drug reactions. Significant anemia, diarrhea, and hypercalcemia were observed. Mild to moderate degrees of malaise/fatigue/lethargy, dizziness/vertigo, hyperglycemia, creatinine increase, nausea, vomiting, weight loss, pedal edema, dyspnea, and granulocytopenia were noted. Merbarone does not have significant activity as a single agent in advanced renal cell carcinoma. 相似文献
132.
133.
134.
135.
Juraj Sprung MD PhD David Distel CRNA Jeffrey Grass MD Eric L. Bloomfield MD Ian C. Lavery MD 《Journal of clinical anesthesia》1996,8(8):662-665
We describe a patient in whom long-term monoamine oxidase (MAO) inhibitor therapy was discontinued 20 days before surgery with general anesthesia. This patient developed severe perioperative hypotension after administration of 10 mg of bupivacaine through an epidural catheter, which was corrected only after potent vasopressor therapy. We attribute this hemodynamic instability to attenuation of this patient's sympathetic tone based on several mechanisms: (1) residual effect of long-term administration of MAO inhibitor that caused a decrease in the number of β-adrenergic receptors (adrenergic subsensitivity due to receptor down-regulation), (2) recovered MAO activity causing effective degradation of sympathetic amines, and (3) combined attenuating effects of general and epidural anesthesia on sympathetic tone. 相似文献
136.
G. Vacca E. Marano V. Brescia Morra R. Lanzillo M. De Vito E. Parente G. Orefice 《Neurological sciences》2007,28(3):133-135
The prevalence of primary headache (PH) in a multiple sclerosis (MS) sample vs. control healthy subjects was investigated at a neurological clinic in 2004–2005: 122 of 238 (51%) MS patients and 57 of
238 (23%) controls proved to be affected by headache. The groups did not differ for the rates of PH types. Headache types
of MS patients were comparable to those of PH patients that were observed at the same institute in a case-control comparison.
First symptoms of headache preceded those of MS in two thirds of cases. Headache features did not significantly change after
MS onset. Comorbidity of MS and PH could be explained by some common clinical and biological traits. 相似文献
137.
Volker Heinemann 《Breast cancer research and treatment》2003,81(1):43-48
Single-agent chemotherapy of metastatic breast cancer is the treatment of choice in patients with slow tumor progression and asymptomatic disease. In this patient group, the choice of drugs is based more on good tolerability than on efficacy. By contrast, symptomatic or rapidly progressing disease requires the use of highly active regimens where more weight is put on reliable antitumor activity. While anthraycline-based combination regimens have set the standard of effective treatment, the addition of docetaxel (and to a lesser extent paclitaxel) has improved tumor response, but failed to induce a consistent prolongation of survival. Based on retrospective analyses, it is hypothesised that the combined use of anthracyclines and taxanes in first-line therapy may be most beneficial in defined subgroups: after adjuvant chemotherapy, in patients with HER-2 gene amplification, possibly also in patients with rapidly progressing visceral disease. 相似文献
138.
139.
Ohne Zusammenfassung 相似文献
140.